These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 15999626)
1. [Thoughts on the "COX-2 story"]. Kurz H Wien Med Wochenschr; 2005 May; 155(9-10):205-6. PubMed ID: 15999626 [No Abstract] [Full Text] [Related]
2. The Vioxx fallout. Palmer K Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592 [No Abstract] [Full Text] [Related]
3. [Study results of routine clinical practice. Do rheumatism patients get substandard care?]. MMW Fortschr Med; 2005 Nov; 147(47):63. PubMed ID: 16370199 [No Abstract] [Full Text] [Related]
4. [Coxibes--bullying of a drug class?]. Müller P; Simon B MMW Fortschr Med; 2008 Jun; 150 Suppl 2():63-4. PubMed ID: 18712125 [No Abstract] [Full Text] [Related]
5. [NSAIDs and COX-2-inhibitors: current status]. Kneitz C; Tony HP; Krüger K Internist (Berl); 2006 May; 47(5):533-4, 536-8, 540. PubMed ID: 16557412 [TBL] [Abstract][Full Text] [Related]
6. [Do selective COX-2-inhibitors increase the risk of myocardial infarction?]. Otterstad JE Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3434-5. PubMed ID: 14713991 [No Abstract] [Full Text] [Related]
7. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Warner TD; Mitchell JA Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021 [No Abstract] [Full Text] [Related]
8. The COX-2 controversy continues ...but NSAIDs are still in the lead. New studies shed light on risks associated with popular arthritis painkillers. Health News; 2006 Aug; 12(8):3-4. PubMed ID: 16913025 [No Abstract] [Full Text] [Related]
9. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Carné X; Cruz N Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277 [No Abstract] [Full Text] [Related]
10. [Coronary risks with NSAID and coxibs. The end of hysteria]. Einecke D MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760 [No Abstract] [Full Text] [Related]
11. What price pain relief? Hochman JS; Shah NR Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335 [No Abstract] [Full Text] [Related]
14. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of pain in rheumatic diseases]. Luttosch F; Baerwald C Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1598-600. PubMed ID: 21809251 [No Abstract] [Full Text] [Related]
19. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors. Aalbers J Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830 [No Abstract] [Full Text] [Related]
20. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]]. Krüger K MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761 [No Abstract] [Full Text] [Related] [Next] [New Search]